Nov 30, 2025, 14:49
Talha Badar ASH25 Key Abstracts to Watch in Acute Lymphoblastic Leukemia
Talha Badar, Hematologist-Oncologist at Mayo Clinic Comprehensive Cancer Center, posted on X:
“ASH25 Key abstracts to watch in acute lymphoblastic leukemia
Overall Takeaways — ASH 2025 ALL Landscape
Rapid movement toward chemo-free or chemo-lite regimens, especially in Ph+ ALL.
TKI + immunotherapy (blina / InO) emerging as new standard-contenders.
CAR-T earlier in therapy (CR1 consolidation and frontline).
Expanding roles for bispecifics and venetoclax-based combinations in R/R ALL.
MRD (especially NGS-MRD) central to future risk-adapted strategies.”
Discover the latest in Hemostasis Today.
-
Apr 29, 2026, 02:52Fengqian Chen: Another Reality Check for the Factor XI Inhibitor Race – Novartis’ Abelacimab Setback
-
Apr 29, 2026, 02:18Arnaud Baldivia: Peri-Procedural Stroke – An Underestimated Emergency in the Operating Room and in the ICU
-
Apr 29, 2026, 02:04Yazhini Selvaraj: What is Plasmapheresis?
-
Apr 29, 2026, 01:48Ushama Pj: Vitamin K – From ICU Emergencies to Long-Term Health
-
Apr 29, 2026, 01:15Yuriy Prokopenko: Honored to Attend the 12th Symposium on Hemostasis
-
Apr 28, 2026, 16:26Andrew Zapfel: The ASH’s Consortium on Newborn Screening in Africa Brought Together Over 40 People From 10 Countries
-
Apr 28, 2026, 16:22Beth Fernandes: Bringing Alaska’s First Civilian Medevac Whole Blood Program To Life
-
Apr 28, 2026, 15:47Dianne E. van der Wal: How Rat and Human Platelet Vesicles Are Different
-
Apr 28, 2026, 15:14Elaheh Mansouri: Platelet Clumping Is a Common Pre-Analytical and Analytical Challenge in Haematology